CN102791285A - 因子VIII-Fc嵌合多肽和杂交多肽及其使用方法 - Google Patents

因子VIII-Fc嵌合多肽和杂交多肽及其使用方法 Download PDF

Info

Publication number
CN102791285A
CN102791285A CN2010800629507A CN201080062950A CN102791285A CN 102791285 A CN102791285 A CN 102791285A CN 2010800629507 A CN2010800629507 A CN 2010800629507A CN 201080062950 A CN201080062950 A CN 201080062950A CN 102791285 A CN102791285 A CN 102791285A
Authority
CN
China
Prior art keywords
seq
amino acid
factor viii
polypeptide
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800629507A
Other languages
English (en)
Chinese (zh)
Inventor
詹妮弗·A·杜蒙
苏珊·洛
艾伦·J·比通蒂
格伦·皮尔斯
阿尔文·卢克
江海燕
拜伦·麦金尼
马特·奥特默
于尔格·萨默
卡伦·纽金特
李连
罗伯特·彼得斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Bioverativ Therapeutics Inc
Biogen MA Inc
Original Assignee
Biogen Idec Hemophilia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Hemophilia Inc filed Critical Biogen Idec Hemophilia Inc
Publication of CN102791285A publication Critical patent/CN102791285A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2010800629507A 2009-12-06 2010-12-06 因子VIII-Fc嵌合多肽和杂交多肽及其使用方法 Pending CN102791285A (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US26707009P 2009-12-06 2009-12-06
US61/267,070 2009-12-06
US28505409P 2009-12-09 2009-12-09
US61/285,054 2009-12-09
US30159210P 2010-02-04 2010-02-04
US61/301,592 2010-02-04
US36306510P 2010-07-09 2010-07-09
US61/363,065 2010-07-09
US37311310P 2010-08-12 2010-08-12
US61/373,113 2010-08-12
US41092910P 2010-11-07 2010-11-07
US61/410,929 2010-11-07
US41967610P 2010-12-03 2010-12-03
US61/419,676 2010-12-03
PCT/US2010/059136 WO2011069164A2 (en) 2009-12-06 2010-12-06 Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof

Publications (1)

Publication Number Publication Date
CN102791285A true CN102791285A (zh) 2012-11-21

Family

ID=44115536

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800629507A Pending CN102791285A (zh) 2009-12-06 2010-12-06 因子VIII-Fc嵌合多肽和杂交多肽及其使用方法

Country Status (30)

Country Link
US (5) US9050318B2 (enExample)
EP (4) EP2506868B1 (enExample)
JP (8) JP5903048B2 (enExample)
KR (1) KR101770849B1 (enExample)
CN (1) CN102791285A (enExample)
AU (6) AU2010325787B2 (enExample)
BR (1) BR112012013502A2 (enExample)
CA (2) CA3121739A1 (enExample)
CO (1) CO6561782A2 (enExample)
CY (2) CY1119919T1 (enExample)
DK (1) DK2506868T3 (enExample)
EA (2) EA025416B1 (enExample)
ES (2) ES2659888T3 (enExample)
HR (2) HRP20180135T1 (enExample)
HU (1) HUE036233T2 (enExample)
IL (2) IL220204B (enExample)
LT (1) LT2506868T (enExample)
ME (1) ME02964B (enExample)
MX (3) MX382693B (enExample)
MY (1) MY159135A (enExample)
NO (1) NO2506868T3 (enExample)
NZ (2) NZ703153A (enExample)
PL (2) PL2506868T3 (enExample)
PT (2) PT3326643T (enExample)
RS (1) RS56957B1 (enExample)
SG (3) SG181130A1 (enExample)
SI (1) SI2506868T1 (enExample)
SM (1) SMT201800099T1 (enExample)
WO (1) WO2011069164A2 (enExample)
ZA (1) ZA201204874B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018113788A1 (zh) * 2016-12-23 2018-06-28 北京辅仁瑞辉生物医药研究院有限公司 重组单链人FVIII-Fc融合蛋白及其应用
CN110383388A (zh) * 2017-01-27 2019-10-25 夏尔人类遗传性治疗公司 药物监测工具
CN111508557A (zh) * 2013-06-20 2020-08-07 百特奥尔塔公司 药物动力学药物给药方案设备和方法
CN114989307A (zh) * 2022-05-11 2022-09-02 河南晟明生物技术研究院有限公司 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
DK2506868T3 (da) 2009-12-06 2018-01-29 Bioverativ Therapeutics Inc Kimæriske og hybride faktor viii-fc-polypeptider og fremgangsmåder til anvendelse deraf
DK2591006T3 (da) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Processerbare enkeltkædede molekyler og polypeptider fremstillet ved anvendelse deraf
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
HUE043894T2 (hu) 2011-06-10 2019-09-30 Bioverativ Therapeutics Inc Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
PL3513804T3 (pl) * 2011-07-08 2022-07-11 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania
EP2737311B1 (en) * 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
CN104271150A (zh) * 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
PL2802668T3 (pl) * 2012-01-12 2019-03-29 Bioverativ Therapeutics Inc. Sposoby zmniejszania immunogenności wobec czynnika krzepnięcia viii u pacjentów poddawanych leczeniu czynnikiem krzepnięcia viii
MX369862B (es) * 2012-02-15 2019-11-25 Bioverativ Therapeutics Inc Composiciones del factor viii y metodos para hacerlas y usarlas.
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US10317376B2 (en) 2012-04-11 2019-06-11 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
US10023628B2 (en) * 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
RS59876B1 (sr) * 2012-07-11 2020-03-31 Bioverativ Therapeutics Inc Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena
EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) * 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
ES2959747T3 (es) * 2013-02-15 2024-02-28 Bioverativ Therapeutics Inc Gen del factor VIII optimizado
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
PL3666283T3 (pl) 2013-03-15 2022-10-03 Bioverativ Therapeutics Inc. Formulacje polipeptydu czynnika viii
US9090697B2 (en) * 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
US10364288B2 (en) 2013-05-24 2019-07-30 Biogen Ma Inc. Anti-GPIIB/IIIA antibodies or uses thereof
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
WO2017180807A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regiment
KR102714760B1 (ko) * 2013-06-28 2024-10-11 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
EP3013359A4 (en) * 2013-06-28 2017-01-25 Biogen MA Inc. Thrombin cleavable linker
EP3027224B1 (en) 2013-07-31 2020-06-03 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
WO2015023894A1 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Recombinant factor viii proteins
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
US10325687B2 (en) * 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP3083933A1 (en) 2013-12-20 2016-10-26 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
PT4176894T (pt) 2014-01-10 2024-05-21 Bioverativ Therapeutics Inc Proteínas quiméricas de fator viii e utilizações destas
WO2015120056A1 (en) 2014-02-04 2015-08-13 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2015148454A1 (en) * 2014-03-28 2015-10-01 Asklepios Biopharmaceutical, Inc. Optimized and modified factor viii genes for gene therapy
PL3134127T3 (pl) 2014-04-25 2020-07-27 Rinat Neuroscience Corp. Koniugaty przeciwciało-lek o dużym ładunku leku
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
EA201700181A1 (ru) 2014-10-14 2017-09-29 Галозим, Инк. Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
WO2017070167A1 (en) 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
EP3411478B1 (en) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimized factor viii genes
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
WO2017222337A1 (ko) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN109843917B (zh) 2016-10-19 2023-10-03 免疫医疗有限责任公司 抗o1抗体及其用途
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US12257288B2 (en) 2016-12-02 2025-03-25 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CA3051862A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
WO2019236739A1 (en) 2018-06-05 2019-12-12 Amgen Inc. Modulating antibody dependent cellular phagocytosis
EP3850006A1 (en) 2018-09-11 2021-07-21 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
WO2020118069A2 (en) 2018-12-06 2020-06-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
WO2020257462A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Recombinant factor viii-fc for treating hemophilia and low bone mineral density
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
JP2023537565A (ja) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
MA68435A1 (fr) * 2022-04-28 2025-04-30 Joint Stock Company "Biocad" Acide nucléique isolé codant pour une protéine de fusion à base de fviii-bdd et d'un peptide de signal hétérologue

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260194A1 (en) * 2003-05-06 2005-11-24 Peters Robert T Immunoglobulin chimeric monomer-dimer hybrids
CN1863556A (zh) * 2003-06-19 2006-11-15 泰诺士公司 用于治疗凝血相关紊乱的组合物和方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235881A (en) * 1978-12-04 1980-11-25 Cort Joseph H Method for producing high potency factor VIII
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
DE3683980D1 (de) 1985-04-12 1992-04-02 Genetics Inst Neue prokoagulierungsproteine.
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
WO2002062377A2 (en) * 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor viii polypeptides
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
HUE026384T2 (en) 2003-05-06 2016-06-28 Biogen Hemophilia Inc VII coagulation factor-FC chimeric proteins for the treatment of hemostasis disorder
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
ES2633916T3 (es) 2004-11-12 2017-09-26 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
JP2009532351A (ja) * 2006-03-31 2009-09-10 バクスター・インターナショナル・インコーポレイテッド ペグ化第ｖｉｉｉ因子
JP5448839B2 (ja) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
WO2009108806A1 (en) * 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
US8800831B2 (en) 2009-08-19 2014-08-12 Larry A. Gray Multi-purpose rack and method thereof
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
JP5739865B2 (ja) * 2009-03-24 2015-06-24 バイエル・ヘルスケア・エルエルシー 第ｖｉｉｉ因子変異体および使用の方法
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
DK2506868T3 (da) 2009-12-06 2018-01-29 Bioverativ Therapeutics Inc Kimæriske og hybride faktor viii-fc-polypeptider og fremgangsmåder til anvendelse deraf
PL3513804T3 (pl) 2011-07-08 2022-07-11 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania
PL2802668T3 (pl) * 2012-01-12 2019-03-29 Bioverativ Therapeutics Inc. Sposoby zmniejszania immunogenności wobec czynnika krzepnięcia viii u pacjentów poddawanych leczeniu czynnikiem krzepnięcia viii
PL3666283T3 (pl) * 2013-03-15 2022-10-03 Bioverativ Therapeutics Inc. Formulacje polipeptydu czynnika viii
JP6083911B2 (ja) 2014-12-19 2017-02-22 花王株式会社 吸収性物品

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260194A1 (en) * 2003-05-06 2005-11-24 Peters Robert T Immunoglobulin chimeric monomer-dimer hybrids
CN1863556A (zh) * 2003-06-19 2006-11-15 泰诺士公司 用于治疗凝血相关紊乱的组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
杨林花等: "凝血因子V和凝血因子Ⅷ活性的变化与冠心病的关系", 《临床血液学杂志》, vol. 17, no. 2, 30 April 2004 (2004-04-30), pages 70 - 72 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111508557A (zh) * 2013-06-20 2020-08-07 百特奥尔塔公司 药物动力学药物给药方案设备和方法
CN111508557B (zh) * 2013-06-20 2024-03-26 武田药品工业株式会社 药物动力学药物给药方案设备和方法
WO2018113788A1 (zh) * 2016-12-23 2018-06-28 北京辅仁瑞辉生物医药研究院有限公司 重组单链人FVIII-Fc融合蛋白及其应用
CN108239151A (zh) * 2016-12-23 2018-07-03 北京辅仁瑞辉生物医药研究院有限公司 重组单链人FVIII-Fc融合蛋白及其应用
CN108239151B (zh) * 2016-12-23 2020-07-03 海门晟斯生物制药有限公司 重组单链人FVIII-Fc融合蛋白及其应用
CN110383388A (zh) * 2017-01-27 2019-10-25 夏尔人类遗传性治疗公司 药物监测工具
CN110383388B (zh) * 2017-01-27 2024-02-20 武田药品工业有限公司 药物监测工具
CN114989307A (zh) * 2022-05-11 2022-09-02 河南晟明生物技术研究院有限公司 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法
CN114989307B (zh) * 2022-05-11 2023-08-01 华兰生物工程股份有限公司 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法

Also Published As

Publication number Publication date
EP3326643A1 (en) 2018-05-30
AU2016213822B2 (en) 2017-08-31
US9050318B2 (en) 2015-06-09
JP6385410B2 (ja) 2018-09-05
IL220204A0 (en) 2012-07-31
WO2011069164A3 (en) 2011-07-28
AU2010325787A1 (en) 2012-07-12
AU2021202912B2 (en) 2024-08-01
DK2506868T3 (da) 2018-01-29
NZ703153A (en) 2015-02-27
AU2017268648B2 (en) 2019-01-31
JP2022051964A (ja) 2022-04-01
JP2013512678A (ja) 2013-04-18
JP2023071969A (ja) 2023-05-23
JP2020019821A (ja) 2020-02-06
AU2010325787A2 (en) 2013-06-06
PT3326643T (pt) 2021-07-12
SG181130A1 (en) 2012-07-30
EP2506868B1 (en) 2017-11-15
US9241978B2 (en) 2016-01-26
JP2025083451A (ja) 2025-05-30
NZ600709A (en) 2015-01-30
EP2506868A2 (en) 2012-10-10
ME02964B (me) 2018-07-20
JP7244688B2 (ja) 2023-03-22
US20130274194A1 (en) 2013-10-17
JP2018024706A (ja) 2018-02-15
JP2017025098A (ja) 2017-02-02
EA025416B1 (ru) 2016-12-30
IL220204B (en) 2018-08-30
PT2506868T (pt) 2018-02-23
AU2024227757A1 (en) 2024-11-21
AU2010325787A8 (en) 2012-07-19
RS56957B1 (sr) 2018-05-31
HRP20180135T1 (hr) 2018-04-06
EA038618B1 (ru) 2021-09-23
EP3906937A1 (en) 2021-11-10
IL260769B (en) 2020-03-31
JP6641340B2 (ja) 2020-02-05
HRP20211010T1 (hr) 2021-09-17
EA201691109A1 (ru) 2017-01-30
MX2012006347A (es) 2012-10-03
CA2782424A1 (en) 2011-06-09
MY159135A (en) 2016-12-15
PL2506868T3 (pl) 2018-06-29
SI2506868T1 (en) 2018-04-30
CY1119919T1 (el) 2018-06-27
CY1124888T1 (el) 2023-01-05
ZA201204874B (en) 2016-06-29
ES2880038T3 (es) 2021-11-23
EA201290443A1 (ru) 2013-06-28
AU2021202912A1 (en) 2021-06-03
CA3121739A1 (en) 2011-06-09
EP3326643B1 (en) 2021-04-07
AU2016213822A1 (en) 2016-09-01
MX382693B (es) 2025-03-13
PL3326643T3 (pl) 2021-10-25
NO2506868T3 (enExample) 2018-04-14
HUE036233T2 (hu) 2018-06-28
US20160199455A1 (en) 2016-07-14
CA2782424C (en) 2021-07-27
SMT201800099T1 (it) 2018-03-08
US20220265780A1 (en) 2022-08-25
BR112012013502A2 (pt) 2017-01-10
EP2506868A4 (en) 2013-07-24
SG10201408049SA (en) 2015-02-27
US11266720B2 (en) 2022-03-08
HK1253887A1 (en) 2019-07-05
KR101770849B1 (ko) 2017-09-05
WO2011069164A2 (en) 2011-06-09
MX336830B (es) 2016-02-03
JP5903048B2 (ja) 2016-04-13
LT2506868T (lt) 2018-02-26
SG10201907152YA (en) 2019-09-27
EP4382170A3 (en) 2024-09-04
KR20120129882A (ko) 2012-11-28
AU2010325787B2 (en) 2016-05-12
US20130108629A1 (en) 2013-05-02
US20190262429A1 (en) 2019-08-29
MX353233B (es) 2018-01-08
AU2017268648A1 (en) 2017-12-21
EP4382170A2 (en) 2024-06-12
JP6062459B2 (ja) 2017-01-18
JP2015083608A (ja) 2015-04-30
ES2659888T3 (es) 2018-03-19
AU2019202969A1 (en) 2019-05-16
CO6561782A2 (es) 2012-11-15

Similar Documents

Publication Publication Date Title
JP7244688B2 (ja) 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法
TWI626947B (zh) 因子viii嵌合及雜交多肽，及其使用方法
EP3552619B1 (en) Factor ix polypeptides and methods of use thereof
EA038705B1 (ru) Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
HK40112150A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
HK40062720A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
HK1253887B (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
HK1176878A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
HK1176878B (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
HK40011493B (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
HK40011493A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
HK1197805B (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
HK1197805A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: Biaogenyi Mongolia Philip sub company

Address before: Massachusetts, USA

Applicant before: Biogen IDEC Hemophilia Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: BIOGEN IDEC HEMOPHILIA INC. TO: BIOGEN HEMOPHILIA INC.

Free format text: CORRECT: ADDRESS; FROM:

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20121121